Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://24paybank.org](https://www.archivebay.com/archive6/images/75821a3e-277c-49ae-a710-17da5518dc85.png)
A complete backup of https://24paybank.org
Are you over 18 and want to see adult content?
![A complete backup of https://buyessayonlinecheap.info](https://www.archivebay.com/archive6/images/2811931b-c843-416c-8a6b-a5d0fe4276e5.png)
A complete backup of https://buyessayonlinecheap.info
Are you over 18 and want to see adult content?
![A complete backup of https://thebeatdfw.com](https://www.archivebay.com/archive6/images/64be7a0b-1a4e-4070-8ba7-7f8e962f2066.png)
A complete backup of https://thebeatdfw.com
Are you over 18 and want to see adult content?
![A complete backup of https://trinitylogistics.com](https://www.archivebay.com/archive6/images/4aea2973-a7be-4004-8caa-5e20a78791f6.png)
A complete backup of https://trinitylogistics.com
Are you over 18 and want to see adult content?
![A complete backup of https://sildenafild7k.com](https://www.archivebay.com/archive6/images/606445f2-1546-4098-b0ba-7f38784d7bb5.png)
A complete backup of https://sildenafild7k.com
Are you over 18 and want to see adult content?
![A complete backup of https://newsmuz.com](https://www.archivebay.com/archive6/images/f8610df8-2b5f-4312-8111-59ca553dadd1.png)
A complete backup of https://newsmuz.com
Are you over 18 and want to see adult content?
![A complete backup of https://suretrader.com](https://www.archivebay.com/archive6/images/6b266e0c-762f-4a34-88a2-c52aef5ddb2b.png)
A complete backup of https://suretrader.com
Are you over 18 and want to see adult content?
![A complete backup of https://marineschepen.nl](https://www.archivebay.com/archive6/images/d7c8dee0-f775-41f6-a7a8-0ea386e410d5.png)
A complete backup of https://marineschepen.nl
Are you over 18 and want to see adult content?
![A complete backup of https://toolboxoffice.it](https://www.archivebay.com/archive6/images/c51cf64c-c584-4f4b-b778-8071fbb901a6.png)
A complete backup of https://toolboxoffice.it
Are you over 18 and want to see adult content?
![A complete backup of https://jerryspinelli.com](https://www.archivebay.com/archive6/images/496d89be-01e5-4b21-9ae0-9c3b3e57475f.png)
A complete backup of https://jerryspinelli.com
Are you over 18 and want to see adult content?
![A complete backup of https://austswim.com.au](https://www.archivebay.com/archive6/images/5059c850-7d69-4934-81e9-0fb6fecd3e2d.png)
A complete backup of https://austswim.com.au
Are you over 18 and want to see adult content?
![A complete backup of https://vardenafil0i0.com](https://www.archivebay.com/archive6/images/0464f8a8-c4c9-4b9a-b8ce-ddd4f9eab39c.png)
A complete backup of https://vardenafil0i0.com
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of akhbaar24.argaam.com/article/detail/479433](https://www.archivebay.com/archive2/aef8cfa2-c862-4846-ba67-425452655098.png)
A complete backup of akhbaar24.argaam.com/article/detail/479433
Are you over 18 and want to see adult content?
![A complete backup of www.bbc.com/news/entertainment-arts-51517973](https://www.archivebay.com/archive2/6bb7b8bf-f84f-478f-8511-89d6877c868b.png)
A complete backup of www.bbc.com/news/entertainment-arts-51517973
Are you over 18 and want to see adult content?
![A complete backup of wwos.nine.com.au/golf/genesis-open-adam-scott-wins-riviera-country-club-tiger-woods-rory-mcilroy/a36e71ad-c](https://www.archivebay.com/archive2/1bb57b63-4fb7-45a0-b6f7-9493bb27af9d.png)
A complete backup of wwos.nine.com.au/golf/genesis-open-adam-scott-wins-riviera-country-club-tiger-woods-rory-mcilroy/a36e71ad-c
Are you over 18 and want to see adult content?
Text
disease.
INVESTOR RELATIONS
InMed’s has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs, which are currently at various stages of clinical and preclinical development:. INM-755 our lead product, which has completed two Phase 1 clinical trials in healthy volunteers, is under development for the treatment of epidermolysis bullosa (“EB”), which is a severe INMED'S RESEARCH OF RARE CANNABINOIDS, INCLUDING InMed is researching and developing rare cannabinoids as potential therapeutics for unmet medical needs. While the most prevalent cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), are widely used for a variety of reasons, evidence suggests there may be greater therapeutic potential in rare cannabinoids that are found in very small traces in the Cannabis plant.CANNABINOL CBN
Cannabinol (CBN) is a rare cannabinoid found in very low levels in the plant. Cannabinol is one of the more than 100 cannabinoid compounds present in the Cannabis plant, albeit at very low levels, which classifies it as a rare or minor cannabinoid. In total, all rare cannabinoids are estimated to make up less than 1% of the Cannabis plant. CBN occurs naturally in cannabis as a degradant ofSTOCK INFORMATION
ROTH Capital Partners. shenry@roth.com. +1 (406) 425-0563. InMed Pharmaceuticals Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding InMed Pharmaceuticals Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of InMed INMED PHARMACEUTICALS ANNOUNCES VOLUNTARY DELISTING FROM All common shares will continue to be listed and tradable on the Nasdaq. VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), todayBOARD OF DIRECTORS
William Garner, MD. Chairman of the Board of Director. Dr. Garner is the founder of EGB Ventures, where he has focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, mergers and acquisitions or IPO transactions. Dr. Garner has extensivedirector-level and
CANNABINOL CBN
Cannabinol formulation for glaucoma. Cannabinol (CBN) is the key active pharmaceutical ingredient (API) in INM-088, which is in preclinical studies as a potential treatment for glaucoma.We are conducting studies to test the ability of CBN to provide protection to the neurons at the back of the eye, referred to as “neuroprotection”, and reduce the intraocular pressure in the eye. SEC FILING | INMED PHARMACEUTICALS INC. UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 . FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 . or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition periodfrom
DEAR SHAREHOLDERS, COLLEAGUES, AND BUSINESS PARTNERS, LETTER TO SHAREHOLDERS / 1 January 20, 2021 . Dear Shareholders, Colleagues, and Business Partners, Without question, 2020 was an extraordinary year in so many INMED PHARMACEUTICALS InMed is the first company to advance the rare cannabinoid, cannabinol (CBN), into a clinical trial as a potential therapeutic to treat disease. INM-755 is a cannabinol topical cream in development for the treatment of epidermolysis bullosa, a devastating genetic skindisease.
INVESTOR RELATIONS
InMed’s has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs, which are currently at various stages of clinical and preclinical development:. INM-755 our lead product, which has completed two Phase 1 clinical trials in healthy volunteers, is under development for the treatment of epidermolysis bullosa (“EB”), which is a severe INMED'S RESEARCH OF RARE CANNABINOIDS, INCLUDING InMed is researching and developing rare cannabinoids as potential therapeutics for unmet medical needs. While the most prevalent cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), are widely used for a variety of reasons, evidence suggests there may be greater therapeutic potential in rare cannabinoids that are found in very small traces in the Cannabis plant.CANNABINOL CBN
Cannabinol (CBN) is a rare cannabinoid found in very low levels in the plant. Cannabinol is one of the more than 100 cannabinoid compounds present in the Cannabis plant, albeit at very low levels, which classifies it as a rare or minor cannabinoid. In total, all rare cannabinoids are estimated to make up less than 1% of the Cannabis plant. CBN occurs naturally in cannabis as a degradant ofSTOCK INFORMATION
ROTH Capital Partners. shenry@roth.com. +1 (406) 425-0563. InMed Pharmaceuticals Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding InMed Pharmaceuticals Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of InMed INMED PHARMACEUTICALS ANNOUNCES VOLUNTARY DELISTING FROM All common shares will continue to be listed and tradable on the Nasdaq. VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), todayBOARD OF DIRECTORS
William Garner, MD. Chairman of the Board of Director. Dr. Garner is the founder of EGB Ventures, where he has focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, mergers and acquisitions or IPO transactions. Dr. Garner has extensivedirector-level and
CANNABINOL CBN
Cannabinol formulation for glaucoma. Cannabinol (CBN) is the key active pharmaceutical ingredient (API) in INM-088, which is in preclinical studies as a potential treatment for glaucoma.We are conducting studies to test the ability of CBN to provide protection to the neurons at the back of the eye, referred to as “neuroprotection”, and reduce the intraocular pressure in the eye. SEC FILING | INMED PHARMACEUTICALS INC. UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 . FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 . or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition periodfrom
DEAR SHAREHOLDERS, COLLEAGUES, AND BUSINESS PARTNERS, LETTER TO SHAREHOLDERS / 1 January 20, 2021 . Dear Shareholders, Colleagues, and Business Partners, Without question, 2020 was an extraordinary year in so manySTOCK INFORMATION
InMed Pharmaceuticals Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding InMed Pharmaceuticals Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of InMed Pharmaceuticals Inc. or its management.STOCK INFORMATION
ROTH Capital Partners. shenry@roth.com. +1 (406) 425-0563. InMed Pharmaceuticals Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding InMed Pharmaceuticals Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of InMedNEWS & EVENTS
Latest Events. May 13, 2021 at 8:00 AM PDT. InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results. May 11, 2021 from 2:30 PM to 2:55 PM EDT. Canaccord Genuity’s 5th Annual Global Cannabis Conference. LEARN ABOUT CANNABINOL, CBN, RARE CANNABINOIDS, EB, GLAUCOMA Epidermolysis bullosa, or EB, is a group of rare genetic skin diseases characterized by fragile skin that can lead to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. It is a debilitating disease affecting a small number of people, thusBOARD OF DIRECTORS
William Garner, MD. Chairman of the Board of Director Dr. Garner is the founder of EGB Ventures, where he has focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, mergers and acquisitions or IPO transactions. FINANCIALS | INMED PHARMACEUTICALS INC. The Investor Relations website contains information about InMed Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts. INMED PHARMACEUTICALS SUBMITS CLINICAL TRIAL APPLICATIONS Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 cream; Additional submissions slated for France, Germany, Greece, and Italy over the next several days and weeks.; Anticipated study on track to begin in 3Q 2021; VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM SEC FILING | INMED PHARMACEUTICALS INC. UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 . FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 . or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition periodfrom
INMED'S CEO, ERIC A. ADAMS, TO PRESENT AT BIO DIGITAL 2021 The Investor Relations website contains information about InMed Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts. CANNABINOL 101: THE SCIENCE OF CANNABINOL (CBN) Cannabinol, or CBN for short, is one of the more than 100 rare cannabinoids found in the Cannabis plant. CBN is found in aged Cannabis and is a degradant of tetrahydrocannabinol (THC) after exposure to air, light and heat. Unlike THC, CBN is generally accepted as non-psychoactive. INMED PHARMACEUTICALS InMed is the first company to advance the rare cannabinoid, cannabinol (CBN), into a clinical trial as a potential therapeutic to treat disease. INM-755 is a cannabinol topical cream in development for the treatment of epidermolysis bullosa, a devastating genetic skindisease.
SCIENCE | INMED PHARMACEUTICALS INC. INM-088 for the treatment of glaucoma. INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye.INVESTOR RELATIONS
InMed’s has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs, which are currently at various stages of clinical and preclinical development:. INM-755 our lead product, which has completed two Phase 1 clinical trials in healthy volunteers, is under development for the treatment of epidermolysis bullosa (“EB”), which is a severeCONTACT INFO
InMed Pharmaceuticals Inc. 1 (604) 669-7207. 1 (778) 945-6800. #310-815 West Hastings St., Vancouver BC, INMED'S RESEARCH OF RARE CANNABINOIDS, INCLUDING InMed is researching and developing rare cannabinoids as potential therapeutics for unmet medical needs. While the most prevalent cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), are widely used for a variety of reasons, evidence suggests there may be greater therapeutic potential in rare cannabinoids that are found in very small traces in the Cannabis plant. LEARN ABOUT CANNABINOL, CBN, RARE CANNABINOIDS, EB, GLAUCOMA Epidermolysis bullosa, or EB, is a group of rare genetic skin diseases characterized by fragile skin that can lead to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. It is a debilitating disease affecting a small number of people, thusCANNABINOL CBN
Cannabinol (CBN) is a rare cannabinoid found in very low levels in the plant. Cannabinol is one of the more than 100 cannabinoid compounds present in the Cannabis plant, albeit at very low levels, which classifies it as a rare or minor cannabinoid. In total, all rare cannabinoids are estimated to make up less than 1% of the Cannabis plant. CBN occurs naturally in cannabis as a degradant of INMED PHARMACEUTICALS ANNOUNCES VOLUNTARY DELISTING FROM All common shares will continue to be listed and tradable on the Nasdaq. VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), todayCANNABINOL CBN
Cannabinol formulation for glaucoma. Cannabinol (CBN) is the key active pharmaceutical ingredient (API) in INM-088, which is in preclinical studies as a potential treatment for glaucoma.We are conducting studies to test the ability of CBN to provide protection to the neurons at the back of the eye, referred to as “neuroprotection”, and reduce the intraocular pressure in the eye. INTEGRASYN™ CANNABINOID MANUFACTURING SYSTEM A cost-effective solution to multi-cannabinoid production. IntegraSyn TM makes cost-efficient use of sophisticated starting materials, requires fewer costly steps all the way through to the end-product, and is designed as a high-yield manufacturing process. We produce high-efficiency enzymes utilizing E. coli biofermentation for use in bulk cannabinoid manufacturing via a biotransformation INMED PHARMACEUTICALS InMed is the first company to advance the rare cannabinoid, cannabinol (CBN), into a clinical trial as a potential therapeutic to treat disease. INM-755 is a cannabinol topical cream in development for the treatment of epidermolysis bullosa, a devastating genetic skindisease.
SCIENCE | INMED PHARMACEUTICALS INC. INM-088 for the treatment of glaucoma. INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye.INVESTOR RELATIONS
InMed’s has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs, which are currently at various stages of clinical and preclinical development:. INM-755 our lead product, which has completed two Phase 1 clinical trials in healthy volunteers, is under development for the treatment of epidermolysis bullosa (“EB”), which is a severeCONTACT INFO
InMed Pharmaceuticals Inc. 1 (604) 669-7207. 1 (778) 945-6800. #310-815 West Hastings St., Vancouver BC, INMED'S RESEARCH OF RARE CANNABINOIDS, INCLUDING InMed is researching and developing rare cannabinoids as potential therapeutics for unmet medical needs. While the most prevalent cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), are widely used for a variety of reasons, evidence suggests there may be greater therapeutic potential in rare cannabinoids that are found in very small traces in the Cannabis plant. LEARN ABOUT CANNABINOL, CBN, RARE CANNABINOIDS, EB, GLAUCOMA Epidermolysis bullosa, or EB, is a group of rare genetic skin diseases characterized by fragile skin that can lead to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. It is a debilitating disease affecting a small number of people, thusCANNABINOL CBN
Cannabinol (CBN) is a rare cannabinoid found in very low levels in the plant. Cannabinol is one of the more than 100 cannabinoid compounds present in the Cannabis plant, albeit at very low levels, which classifies it as a rare or minor cannabinoid. In total, all rare cannabinoids are estimated to make up less than 1% of the Cannabis plant. CBN occurs naturally in cannabis as a degradant of INMED PHARMACEUTICALS ANNOUNCES VOLUNTARY DELISTING FROM All common shares will continue to be listed and tradable on the Nasdaq. VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), todayCANNABINOL CBN
Cannabinol formulation for glaucoma. Cannabinol (CBN) is the key active pharmaceutical ingredient (API) in INM-088, which is in preclinical studies as a potential treatment for glaucoma.We are conducting studies to test the ability of CBN to provide protection to the neurons at the back of the eye, referred to as “neuroprotection”, and reduce the intraocular pressure in the eye. INTEGRASYN™ CANNABINOID MANUFACTURING SYSTEM A cost-effective solution to multi-cannabinoid production. IntegraSyn TM makes cost-efficient use of sophisticated starting materials, requires fewer costly steps all the way through to the end-product, and is designed as a high-yield manufacturing process. We produce high-efficiency enzymes utilizing E. coli biofermentation for use in bulk cannabinoid manufacturing via a biotransformation ABOUT | INMED PHARMACEUTICALS InMed’s has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs, which are currently at various stages of clinical and preclinical development:. INM-755, our lead product, is under development for the treatment of epidermolysis bullosa (“EB”), which is a severe genetic skin disorder. InMed has filed Clinical Trial Applications in SCIENCE | INMED PHARMACEUTICALS INC. INM-088 for the treatment of glaucoma. INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye. MANAGEMENT | INMED PHARMACEUTICALS INC. Eric A. Adams, MIBS. Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than CAREERS | INMED PHARMACEUTICALS INC. Join Our Team. At InMed, we value innovation, integrity, teamwork, and mutual respect in our employees. We want to hear from you if you are interested in making a difference in the lives of patients. If you would like to apply to a currently available career opportunity, please submit your CV and cover letter in PDF format tohr@inmedpharma.com.
INVESTOR ALERT
By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed LETTER TO SHAREHOLDERS The year ahead holds tremendous promise for InMed and we are dedicated to fully realizing the Compa- ny’s true potential. On the scientific front, we will continue to expand and validate our core technologies by seeking patents and peer-reviewed publications of our unique approach to disease target selection, validation, and drugdevelopment.
SCIENCE | DISCOVERY AND DEVELOPMENT OF CANNABINOID MEDICINE The discovery of the first cannabinoid receptors occurred in the 1980s and helped to clarify their role. These receptors are common in mammals, birds, fish and reptiles. There are currently two known types of cannabinoid receptors: CB1 and CB2. CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in thelimbic
FREQUENTLY ASKED QUESTIONS FAQS INMED PHARMACEUTICALS Answers to InMed's frequently asked questions. Find the answers to InMed's FAQs - such as questions on the company's NASDAQ listingapplication.
WHAT IS EPIDERMOLYSIS BULLOSA? LEARN ABOUT RARE GENETIC What is Epidermolysis Bullosa (EB)? Epidermolysis bullosa, or EB, is a group of rare genetic skin diseases characterized by fragile skin that can lead to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. CANNABIS TREATMENTS FOR GLAUCOMA, OCULAR DISEASE, EYE DISEASE Cannabis administered systemically may cause long-term glaucoma damage . Although Cannabis does lower the IOP temporarily, IOP lowering is only one consideration in slowing the optic nerve damage of glaucoma. For instance, there is a growing body of evidence that inadequate blood supply to the optic nerve may also contribute to glaucomadamage.
INMED PHARMACEUTICALS InMed is the first company to advance the rare cannabinoid, cannabinol (CBN), into a clinical trial as a potential therapeutic to treat disease. INM-755 is a cannabinol topical cream in development for the treatment of epidermolysis bullosa, a devastating genetic skindisease.
SCIENCE | INMED PHARMACEUTICALS INC. INM-088 for the treatment of glaucoma. INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye.INVESTOR RELATIONS
InMed’s has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs, which are currently at various stages of clinical and preclinical development:. INM-755 our lead product, which has completed two Phase 1 clinical trials in healthy volunteers, is under development for the treatment of epidermolysis bullosa (“EB”), which is a severeCONTACT INFO
InMed Pharmaceuticals Inc. 1 (604) 669-7207. 1 (778) 945-6800. #310-815 West Hastings St., Vancouver BC, INMED'S RESEARCH OF RARE CANNABINOIDS, INCLUDING InMed is researching and developing rare cannabinoids as potential therapeutics for unmet medical needs. While the most prevalent cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), are widely used for a variety of reasons, evidence suggests there may be greater therapeutic potential in rare cannabinoids that are found in very small traces in the Cannabis plant. LEARN ABOUT CANNABINOL, CBN, RARE CANNABINOIDS, EB, GLAUCOMA Epidermolysis bullosa, or EB, is a group of rare genetic skin diseases characterized by fragile skin that can lead to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. It is a debilitating disease affecting a small number of people, thusCANNABINOL CBN
Cannabinol (CBN) is a rare cannabinoid found in very low levels in the plant. Cannabinol is one of the more than 100 cannabinoid compounds present in the Cannabis plant, albeit at very low levels, which classifies it as a rare or minor cannabinoid. In total, all rare cannabinoids are estimated to make up less than 1% of the Cannabis plant. CBN occurs naturally in cannabis as a degradant of INMED PHARMACEUTICALS ANNOUNCES VOLUNTARY DELISTING FROM All common shares will continue to be listed and tradable on the Nasdaq. VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), todayCANNABINOL CBN
Cannabinol formulation for glaucoma. Cannabinol (CBN) is the key active pharmaceutical ingredient (API) in INM-088, which is in preclinical studies as a potential treatment for glaucoma.We are conducting studies to test the ability of CBN to provide protection to the neurons at the back of the eye, referred to as “neuroprotection”, and reduce the intraocular pressure in the eye. INTEGRASYN™ CANNABINOID MANUFACTURING SYSTEM A cost-effective solution to multi-cannabinoid production. IntegraSyn TM makes cost-efficient use of sophisticated starting materials, requires fewer costly steps all the way through to the end-product, and is designed as a high-yield manufacturing process. We produce high-efficiency enzymes utilizing E. coli biofermentation for use in bulk cannabinoid manufacturing via a biotransformation INMED PHARMACEUTICALS InMed is the first company to advance the rare cannabinoid, cannabinol (CBN), into a clinical trial as a potential therapeutic to treat disease. INM-755 is a cannabinol topical cream in development for the treatment of epidermolysis bullosa, a devastating genetic skindisease.
SCIENCE | INMED PHARMACEUTICALS INC. INM-088 for the treatment of glaucoma. INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye.INVESTOR RELATIONS
InMed’s has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs, which are currently at various stages of clinical and preclinical development:. INM-755 our lead product, which has completed two Phase 1 clinical trials in healthy volunteers, is under development for the treatment of epidermolysis bullosa (“EB”), which is a severeCONTACT INFO
InMed Pharmaceuticals Inc. 1 (604) 669-7207. 1 (778) 945-6800. #310-815 West Hastings St., Vancouver BC, INMED'S RESEARCH OF RARE CANNABINOIDS, INCLUDING InMed is researching and developing rare cannabinoids as potential therapeutics for unmet medical needs. While the most prevalent cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), are widely used for a variety of reasons, evidence suggests there may be greater therapeutic potential in rare cannabinoids that are found in very small traces in the Cannabis plant. LEARN ABOUT CANNABINOL, CBN, RARE CANNABINOIDS, EB, GLAUCOMA Epidermolysis bullosa, or EB, is a group of rare genetic skin diseases characterized by fragile skin that can lead to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. It is a debilitating disease affecting a small number of people, thusCANNABINOL CBN
Cannabinol (CBN) is a rare cannabinoid found in very low levels in the plant. Cannabinol is one of the more than 100 cannabinoid compounds present in the Cannabis plant, albeit at very low levels, which classifies it as a rare or minor cannabinoid. In total, all rare cannabinoids are estimated to make up less than 1% of the Cannabis plant. CBN occurs naturally in cannabis as a degradant of INMED PHARMACEUTICALS ANNOUNCES VOLUNTARY DELISTING FROM All common shares will continue to be listed and tradable on the Nasdaq. VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), todayCANNABINOL CBN
Cannabinol formulation for glaucoma. Cannabinol (CBN) is the key active pharmaceutical ingredient (API) in INM-088, which is in preclinical studies as a potential treatment for glaucoma.We are conducting studies to test the ability of CBN to provide protection to the neurons at the back of the eye, referred to as “neuroprotection”, and reduce the intraocular pressure in the eye. INTEGRASYN™ CANNABINOID MANUFACTURING SYSTEM A cost-effective solution to multi-cannabinoid production. IntegraSyn TM makes cost-efficient use of sophisticated starting materials, requires fewer costly steps all the way through to the end-product, and is designed as a high-yield manufacturing process. We produce high-efficiency enzymes utilizing E. coli biofermentation for use in bulk cannabinoid manufacturing via a biotransformation ABOUT | INMED PHARMACEUTICALS InMed’s has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs, which are currently at various stages of clinical and preclinical development:. INM-755, our lead product, is under development for the treatment of epidermolysis bullosa (“EB”), which is a severe genetic skin disorder. InMed has filed Clinical Trial Applications in SCIENCE | INMED PHARMACEUTICALS INC. INM-088 for the treatment of glaucoma. INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye. MANAGEMENT | INMED PHARMACEUTICALS INC. Eric A. Adams, MIBS. Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than CAREERS | INMED PHARMACEUTICALS INC. Join Our Team. At InMed, we value innovation, integrity, teamwork, and mutual respect in our employees. We want to hear from you if you are interested in making a difference in the lives of patients. If you would like to apply to a currently available career opportunity, please submit your CV and cover letter in PDF format tohr@inmedpharma.com.
INVESTOR ALERT
By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed LETTER TO SHAREHOLDERS The year ahead holds tremendous promise for InMed and we are dedicated to fully realizing the Compa- ny’s true potential. On the scientific front, we will continue to expand and validate our core technologies by seeking patents and peer-reviewed publications of our unique approach to disease target selection, validation, and drugdevelopment.
SCIENCE | DISCOVERY AND DEVELOPMENT OF CANNABINOID MEDICINE The discovery of the first cannabinoid receptors occurred in the 1980s and helped to clarify their role. These receptors are common in mammals, birds, fish and reptiles. There are currently two known types of cannabinoid receptors: CB1 and CB2. CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in thelimbic
FREQUENTLY ASKED QUESTIONS FAQS INMED PHARMACEUTICALS Answers to InMed's frequently asked questions. Find the answers to InMed's FAQs - such as questions on the company's NASDAQ listingapplication.
WHAT IS EPIDERMOLYSIS BULLOSA? LEARN ABOUT RARE GENETIC What is Epidermolysis Bullosa (EB)? Epidermolysis bullosa, or EB, is a group of rare genetic skin diseases characterized by fragile skin that can lead to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. CANNABIS TREATMENTS FOR GLAUCOMA, OCULAR DISEASE, EYE DISEASE Cannabis administered systemically may cause long-term glaucoma damage . Although Cannabis does lower the IOP temporarily, IOP lowering is only one consideration in slowing the optic nerve damage of glaucoma. For instance, there is a growing body of evidence that inadequate blood supply to the optic nerve may also contribute to glaucomadamage.
Skip to content
* Science____
* INM-755 for Epidermolysis Bullosa * INM-088 for Glaucoma * IntegraSyn™ Cannabinoid Manufacturing * InMed’s Research of Rare Cannabinoids* Investor____
* News & Events
* Stock Information
* Corporate Governance* Financials
* Filings
* IR Resources
* About____
* Management
* Board of Directors * Scientific Advisory Board * Partners and Collaborators* Events Calendar
* FAQ
* Careers
* Learn____
* What is Cannabinol (CBN)? * What is Epidermolysis Bullosa (EB)?* What is Glaucoma?
* GMP Manufacturing Standards by Product Type * Cannabis Treatments for Glaucoma * Cannabinoid Science * Articles and Videos* Contact
__ Menu
* Science____
* INM-755 for Epidermolysis Bullosa * INM-088 for Glaucoma * IntegraSyn™ Cannabinoid Manufacturing * InMed’s Research of Rare Cannabinoids* Investor____
* News & Events
* Stock Information
* Corporate Governance* Financials
* Filings
* IR Resources
* About____
* Management
* Board of Directors * Scientific Advisory Board * Partners and Collaborators* Events Calendar
* FAQ
* Careers
* Learn____
* What is Cannabinol (CBN)? * What is Epidermolysis Bullosa (EB)?* What is Glaucoma?
* GMP Manufacturing Standards by Product Type * Cannabis Treatments for Glaucoma * Cannabinoid Science * Articles and Videos* Contact
* Science__
* INM-755 for Epidermolysis Bullosa * INM-088 for Glaucoma * IntegraSyn™ Cannabinoid Manufacturing * InMed’s Research of Rare Cannabinoids* Investor__
* News & Events
* Stock Information
* Corporate Governance* Financials
* Filings
* IR Resources
* About__
* Management
* Board of Directors * Scientific Advisory Board * Partners and Collaborators* Events Calendar
* FAQ
* Careers
* Learn__
* What is Cannabinol (CBN)? * What is Epidermolysis Bullosa (EB)?* What is Glaucoma?
* GMP Manufacturing Standards by Product Type * Cannabis Treatments for Glaucoma * Cannabinoid Science * Articles and Videos* Contact
__ Menu
* Science__
* INM-755 for Epidermolysis Bullosa * INM-088 for Glaucoma * IntegraSyn™ Cannabinoid Manufacturing * InMed’s Research of Rare Cannabinoids* Investor__
* News & Events
* Stock Information
* Corporate Governance* Financials
* Filings
* IR Resources
* About__
* Management
* Board of Directors * Scientific Advisory Board * Partners and Collaborators* Events Calendar
* FAQ
* Careers
* Learn__
* What is Cannabinol (CBN)? * What is Epidermolysis Bullosa (EB)?* What is Glaucoma?
* GMP Manufacturing Standards by Product Type * Cannabis Treatments for Glaucoma * Cannabinoid Science * Articles and Videos* Contact
Leader in the Therapeutic Development of Cannabinol (CBN) InMed is the first company to advance the rare cannabinoid, cannabinol (CBN), into a clinical trial as a potential therapeutic to treatdisease.
Learn More
INM-755 for Epidermolysis Bullosa INM-755 is a cannabinol topical cream in development for the treatment of epidermolysis bullosa, a devastating genetic skin disease. InMed has filed Clinical Trial Applications in several countries to begin Phase 2 clinical trials.Learn More
Rare Cannabinoids for Ocular Diseases INM-088 is a cannabinol formulation under development for glaucoma. Preclinical studies indicate CBN’s potential to provide neuroprotection as well as reduce intraocular pressure in the eye.Learn More
Game-Changing Cannabinoid Manufacturing System IntegraSyn™ is InMed’s integrated cannabinoid manufacturing system to efficiently produce bio-identical cannabinoids.Learn More
Successful Track Record InMed’s management team has a proven track record of success in delivering on its milestones and advancing new pharmaceutical therapies for diseases with high unmet medical needs.Learn More
Leader in the Therapeutic Development of Cannabinol (CBN) InMed is the first company to advance the rare cannabinoid, cannabinol (CBN), into a clinical trial as a potential therapeutic to treatdisease.
Learn More
INM-755 for Epidermolysis Bullosa INM-755 is a cannabinol topical cream in development for the treatment of epidermolysis bullosa, a devastating genetic skin disease. InMed has filed Clinical Trial Applications in several countries to begin Phase 2 clinical trials.Learn More
Rare Cannabinoids for Ocular Diseases INM-088 is a cannabinol formulation under development for glaucoma. Preclinical studies indicate CBN’s potential to provide neuroprotection as well as reduce intraocular pressure in the eye.Learn More
Game-Changing Cannabinoid Manufacturing System IntegraSyn™ is InMed’s integrated cannabinoid manufacturing system to efficiently produce bio-identical cannabinoids.Learn More
Successful Track Record InMed’s management team has a proven track record of success in delivering on its milestones and advancing new pharmaceutical therapies for diseases with high unmet medical needs.Learn More
Leader in the Therapeutic Development of Cannabinol (CBN) InMed is the first company to advance the rare cannabinoid, cannabinol (CBN), into a clinical trial as a potential therapeutic to treatdisease.
Learn More
INM-755 for Epidermolysis Bullosa INM-755 is a cannabinol topical cream in development for the treatment of epidermolysis bullosa, a devastating genetic skin disease. InMed has filed Clinical Trial Applications in several countries to begin Phase 2 clinical trials.Learn More
Rare Cannabinoids for Ocular Diseases INM-088 is a cannabinol formulation under development for glaucoma. Preclinical studies indicate CBN’s potential to provide neuroprotection as well as reduce intraocular pressure in the eye.Learn More
Game-Changing Cannabinoid Manufacturing System IntegraSyn™ is InMed’s integrated cannabinoid manufacturing system to efficiently produce bio-identical cannabinoids.Learn More
Successful Track Record InMed’s management team has a proven track record of success in delivering on its milestones and advancing new pharmaceutical therapies for diseases with high unmet medical needs.Learn More
EXPERTISE IN THE PHARMACEUTICAL DEVELOPMENT OF RARE CANNABINOIDS InMed is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates to treat several diseases with high unmet medical needs. PROGRAMS FOR SKIN AND OCULAR DISEASE Two of InMed’s most advanced programs focus on rare cannabinoid formulations for skin and ocular diseases. Cannabinol (CBN) is the active pharmaceutical ingredient (API) in InMed’s two lead programs for epidermolysis bullosa and glaucoma. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream for epidermolysis bullosa,
a devastating, rare genetic skin disease. InMed’s second program, INM-088, is a CBN-based product being developed as a topical ocular formulation for glaucoma and is currently in preclinical studies. Learn more about our programs in epidermolysis bullosaand glaucoma
.
A GOAL TO DELIVER SAFE AND EFFECTIVE CANNABINOID TREATMENTS InMed’s preclinical studies of cannabinol (CBN) demonstrated an excellent safety profile. In preclinical studies, CBN showed the potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). The findings from these extensive studies supported the advancement of INM-755 cream as an investigational treatment for epidermolysis bullosa (EB) into Phase 1 clinical studies in healthy volunteers. Two Phase 1 studies have been completed and Clinical Trial Applications have been filed in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa.learn More
INTEGRATED CANNABINOID MANUFACTURING SYSTEM TO PRODUCE PHARMACEUTICAL-GRADE, BIO-IDENTICAL CANNABINOIDS While rare cannabinoids may hold tremendous potential as new treatments for diseases with high unmet medical needs, it is not economically feasible to extract and purify most of them directly from the plant due to the very low quantities available. IntegraSynTM, InMed’s integrated cannabinoid manufacturing system, uses multiple standard pharmaceutical processes to enable the production of cannabinoids with bio-identical structures as compared to those found in nature. The IntegraSynTM manufacturing approach has been able to achieve a level of 2g/L cannabinoid yield, a milestone that signals commercial viability and supports advancement to large-scale production.learn More
Click
to enlarge
SUCCESSFUL TRACK RECORD InMed aims to transform patients’ lives by developing safe and effective cannabinoid-based therapeutics across a broad spectrum of diseases with high unmet medical needs. Since our formation in 2014, we have fortified our capital position, assembled a world class leadership team with a successful track record in drug development, strengthened our potentially game-changing technologies, and advanced our novel, cannabinoid-based pipeline ofdrug candidates.
Today, InMed is acutely focused on building a technologically advanced cannabinoid pharmaceutical company unlike any other.learn More
LATEST NEWS
INMED PHARMACEUTICALS SUBMITS CLINICAL TRIAL APPLICATIONS TO EVALUATE INM-755 (CANNABINOL) CREAM IN A PHASE 2 TRIAL FOR EPIDERMOLYSISBULLOSA
April 28, 2021 Learn More INMED PHARMACEUTICALS ANNOUNCES VOLUNTARY DELISTING FROM TSX April 27, 2021 Learn More INMED PHARMACEUTICALS ACHIEVES 2G/L CANNABINOID YIELD WITHINTEGRASYN™
April 26, 2021 Learn More INMED TO PRESENT AT VIRTUAL CONFERENCES IN MARCH 2021 March 3, 2021 Learn More INMED ANNOUNCES CLOSING OF US$4.5 MILLION PRIVATE PLACEMENT February 16, 2021 Learn More INMED PHARMACEUTICALS REPORTS SECOND QUARTER FISCAL 2021 FINANCIALRESULTS
February 11, 2021 Learn MoreINMED
PHARMACEUTICALS REPORTS THIRD QUARTER FISCAL 2021 FINANCIAL RESULTS May 13, 2021Learn MoreINMED
PHARMACEUTICALS TO REPORT THIRD QUARTER FISCAL 2021 FINANCIAL RESULTS May 06, 2021Learn MoreINMED
TO PRESENT AT CANACCORD GENUITY’S 5TH ANNUAL GLOBAL CANNABIS CONFERENCE ON MAY 11TH, 2021 May 04, 2021Learn MoreINMED
PHARMACEUTICALS SUBMITS CLINICAL TRIAL APPLICATIONS TO EVALUATE INM-755 (CANNABINOL) CREAM IN A PHASE 2 TRIAL FOR EPIDERMOLYSISBULLOSA
Apr 28, 2021Learn MoreINMED
PHARMACEUTICALS ANNOUNCES VOLUNTARY DELISTING FROM TSX Apr 27, 2021Learn MoreINMED
PHARMACEUTICALS ACHIEVES 2G/L CANNABINOID YIELD WITH INTEGRASYN™ Apr 26, 2021Learn MoreSee all news
INVESTOR ALERTS
Sign up to receive news releases from InMed Pharmaceuticals.Learn More
INM-755
A cannabinol (CBN) cream under development for the treatment for Epidermolysis BullosaLearn More
INM-088
A cannabinol (CBN) formulation in preclinical development for the treatment of glaucomaLearn More
INTEGRASYN™
InMed’s flexible, integrated cannabinoid manufacturing system to efficiently produce pharmaceutical-grade, bio-identicalcannabinoids.
Learn More
#310 – 815 West Hastings St. Vancouver, BC, CanadaV6C 1B4
Science
* INM-755 for Epidermolysis Bullosa * INM-088 for Glaucoma * IntegraSyn™ Cannabinoid Manufacturing * InMed’s Research of Rare CannabinoidsInvestor
* News & Events
* Stock Information
* Corporate Governance* Financial
s
* Filings
* IR Resources
About
* Management
* Board of Directors * Scientific Advisory Board * Partners and Collaborators* Events Calendar
* FAQ
* Careers
Learn
* What is Cannabinol (CBN)? * What is Epidermolysis Bullosa (EB)?* What is Glaucoma?
* GMP Manufacturing Standards by Product Type * Cannabinoids for Glaucoma * Cannabinoid Science * Articles and Videos Copyright 2021 InMed Pharmaceuticals Inc.* Privacy Policy
* Terms of Use
* Legal Disclaimer
* Find Us On:
* __
* __
* __
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0